Burns
Conditions
Keywords
Resuscitation, Crystalloids, Inflammation
Brief summary
This is a pilot study, but the investigators will also observe key immunological events with potential significance. The global objective is to study the inflammatory profiles of PlasmaLyte and Ringer's Lactate used in the initial massive fluid resuscitation of severely burned patients. On the long term, the investigators will identify the crystalloid that prevents hyperactivation of macrophages and death of severely burned patients.
Detailed description
The investigators have 4 specific objectives. First, the investigators will compare the activation profiles of macrophages and neutrophils in patients admitted to the severely burned unit with regards to the crystalloids used. Secondly, the investigators will assess the differences in the SOFA scores according to the crystalloids used. Thirdly, the investigators will evaluate the impact of crystalloids in the quality of skin grafts performed on severely burned patients. Lastly, with the help of a patient partner, the investigators will determine the right immunological terminology of the study for a non-scientific population.
Interventions
PROCEDUREPlasmaLyte for fluid resuscitation
Fluid resuscitation is a critical and essential part in the treatment of severely burned patients. Patients randomized for this arm will be submitted to PlasmaLyte infusion (as clinically prescribed).
PROCEDURERinger's Lactate for fluid resuscitation
Fluid resuscitation is a critical and essential part in the treatment of severely burned patients. Patients randomized for this arm will be submitted to Ringer's Lactate infusion (as clinically prescribed).
Sponsors
Centre hospitalier de l'Université de Montréal (CHUM)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Intervention model description
Patients admitted to the severely burned unit will be randomized by the research nurse to either received PlasmaLyte or Ringer's Lactate. Research Nurse will then advise the treating team.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* admission to the CHUM * more than 20% of burned area * first blood withdrawal in the first 24 hours following burn
Exclusion criteria
* immunosuppression * chemotherapy 6 months before admission * radiotherapy 6 months before admission * autoimmune diseases * neoplasia * pregnancy * severe infections * cardiac dysfunctions * renal dysfunction * hepatic dysfunctions * Hepatitis C * HIV
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in monocyte phenotype from admission to day 10 | Pre-infusion to day 10 post-infusion | Following blood draws, monocytes will be subjected to flow cytometry for phenotype evaluation. |
Countries
Canada
Outcome results
None listed